Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS6297228 B1
Publication typeGrant
Application numberUS 09/445,237
PCT numberPCT/US1998/012711
Publication dateOct 2, 2001
Filing dateJun 18, 1998
Priority dateNov 22, 1991
Fee statusLapsed
Also published asCA2296558A1, DE69825906D1, DE69825906T2, EP1003553A1, EP1003553B1, US5770592, WO1999003503A1
Publication number09445237, 445237, PCT/1998/12711, PCT/US/1998/012711, PCT/US/1998/12711, PCT/US/98/012711, PCT/US/98/12711, PCT/US1998/012711, PCT/US1998/12711, PCT/US1998012711, PCT/US199812711, PCT/US98/012711, PCT/US98/12711, PCT/US98012711, PCT/US9812711, US 6297228 B1, US 6297228B1, US-B1-6297228, US6297228 B1, US6297228B1
InventorsAbbot F. Clark
Original AssigneeAlcon Manufacturing, Ltd.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Use of angiostatic steroids in photodynamic therapy
US 6297228 B1
Abstract
Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steriod are disclosed.
Images(1)
Previous page
Next page
Claims(5)
I claim:
1. A method for preventing and treating ocular neovascularization, which comprises the use of PDT in combination with a compound selected from the group consisting of: 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate, 4,9(11)-Pregnadien-17α,21-diol-3,20-dione, 11-Epicortisol, 17alpha-Hydroxyprogesterone, Tetrahydrocortexolone (THS), and Tetrahydrocortisol (TBF).
2. The method of claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate.
3. The method of claim 1 wherein the angiostatic steroid is 4,9(11)-Pregnadien-17α,21-diol-3,20-dione.
4. The method of claim 1 wherein the angiostatic steroid is administered at a concentration of about 0.01 to 15.0 weight percent.
5. The method of claim 4 wherein the angiostatic steroid is administered at a concentration of about 0.1-7.5 weight percent.
Description

This application is a continuation of Ser. No. 08/898,154 filed Jul. 16, 1997 U.S. Pat. No. 5,770,592, which is a continuation of Ser. No. 08/342,524 filed Nov. 2, 1994 now U.S. Pat. No. 5,679,666, and a continuation of Ser. No. 07/776,169, filed Nov. 22, 1991.

FIELD OF THE INVENTION

This invention relates to the use of angiostatic steroids in photodynamic therapy (PDT).

DESCRIPTION OF THE RELATED ART

Steroids functioning to inhibit angiogenesis in the presence of heparin or specific heparin fragments are disclosed in Crum, et al., A New Class of Steroids Inhibits Angiogenesis In The Presence of Heparin or Heparin Fragment, Science, 230:375-378, December 20, 1985. The authors refer to such steroids as “angiostatic” steroids. Included in the new class of steroids found to be angiostatic are cortisol, cortexolone, and several dihydro and tetrahydro derivatives. In a follow up study directed to testing a hypothesis as to the mechanism by which the steroids inhibit angiogenesis, it was shown that heparin/angiostatic steroid compositions caused dissolution of the basement membrane scaffolding to which anchorage dependent endothelia are attached resulting in capillary involution; see, Ingber, et al. A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids. Induction of Capillary Basement Membrane Dissolution, Endocrinology 119:768-775, 1986.

A group of tetrahydrosteroids useful in inhibiting angiogenesis is disclosed in U.S. Pat. No. 4,975,537, issued to Aristoff, et al. The compounds are disclosed for use in treating head trauma, spinal trauma, septic or traumatic shock, stroke, and hemorrhage shock. In addition, the patent discusses the utility of these compounds in embryo implantation and in the treatment of cancer, arthritis, and arteriosclerosis. The compounds are not disclosed for ophthalmic use. Some of the tetrahydrosteroids disclosed in Aristoff, et al. are disclosed in U.S. Pat. No. 4,771,042 in combination with heparin or a heparin fragment for inhibiting angiogenesis in a warm blooded animal. The patent does not disclose the combination for ophthalmic use.

Compositions of hydrocortisone, “tetrahydrocortisol-S,” and U-72,745G, each in combination with a beta cyclodextrin have been shown to inhibit corneal neovascularization. Li, et al., Angiostatic Steroids Potentiated by Sulphated Cyclodextrin Inhibit Corneal Neovascularization, Investigative Ophthalmology and Visual Science, 32(11):2898-2905, October, 1991. The steroids alone reduce neovascularization somewhat but are not effective alone in providing for regression of neovascularization.

There are currently no effective therapies for the treatment of ocular neovascular diseases which do not include the destruction of healthy viable tissue. Although panretinal photocoagulation is the current medical practice for the treatment of diabetic retinopathy and is effective in inhibiting diabetic retinal neovascularization, this procedure destroys healthy peripheral retinal tissue. This destruction of healthy tissue decreases the retinal metabolic demand and thereby reduces retinal ischemia driven neovascularization. A recent new laser procedure is being tested for the inhibition of ocular neovascularization. Photodynamic therapy (PDT) is a procedure in which a photoactivatable dye is given systemically followed by laser activation of the dye in the eye at the site of new blood vessel formation (Asrani & Zeimer, Br J Ophthalmol, 79(8):776-770, August, 1995; Asrani et al, Invest Ophthalmol. Vis Sci, 38(13);2702-2710, December, 1997; Husain et al, Ophthalmology, 104(8):242-1250, August, 1997; Lin et al, Curr Eye Res, 13(7):513-522, July, 1994.) The photoactivated drug generates free oxygen radicals which seal the newly formed blood vessels. This procedure has been used in patients with the exudative form of macular degeneration and many patients show regression of their subretinal neovascular membranes. Unfortunately, it appears that the PDT induced inhibition of neovascularization is transient lasting only 6-12 weeks (Gragoudas et al, Investigative Ophthalmology & Visual Science, 38(4):S17; Mar. 15, 1997; Sickenberg et al, Investigative Ophthalmology & Visual Science, 38(4):S92, Mar. 15, 1997; Thomas et al, Investigative Ophthalmology & Visual Science, 39(4):S242, Mar. 15, 1998.)

The subject matter of the present invention involves combining the PDT induced regression of ocular neovascular tissue with agents, such as angiostatic steroids, which inhibit new blood vessel formation.

SUMMARY OF THE INVENTION

This invention is directed to methods for treating ocular neovascular diseases by combining the use of PDT with particular angiostatic steroids.

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1—Compares the ability of angiostatic steroids to inhibit neovascularization in the rabbit cornea.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The development of blood vessels for the purpose of sustaining vital tissue is known as angiogenesis or neovascularization. Agents which inhibit neovascularization are known by a variety of terms such as angiostatic, angiolytic, or angiotropic agents. For purposes of this specification, the term “angiostatic agent” means compounds which can be used to inhibit neovascularization.

Ocular neovascularization has not been successfully treated in the past. Neovascularization of tissues in the front of the eye (i.e. the cornea, iris, and the trabecular meshwork) and other conditions, including conditions in the back of the eye, for example, retinal, subretinal, macular, and optical nerve head neovascularization, can be prevented and treated by administration of the steroids of this invention. The angiostatic agents are useful in preventing and treating ocular neovascularization, including providing for the regression of neovascularization.

The angiostatic agents of this invention are steroids available from Steraloids, Inc., Wilton, N.H. and have the following structures and names:

The above structures include all pharmaceutically acceptable salts of the angiostatic steroids.

The preferred angiostatic steroids are 4,9(11)-pregnadien-17α,21-diol-3,20-dione and 4,9(11)-pregnadien-17α,21-diol-3,20-dione-21-acetate (anecortave acetate).

The angiostatic steroids in combination with PDT are useful in preventing and treating any ocular neovascularization, including, but not limited to: retinal diseases (diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, age related macular degeneration (ARMD) due to subretinal neovascularization); rubeosis iritis; inflammatory diseases; chronic uveitis; neoplasms (retinoblastoma, pseudoglioma); Fuchs' heterochromic iridocyclitis; neovascular glaucoma; corneal neovascularization (inflammatory, transplantation, developmental hypoplasia of the iris); neovascularization resulting following a combined vitrectomy and lensectomy; vascular diseases (retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, carotid artery ischemia); neovascularization of the optic nerve; and neovascularization due to penetration of the eye or contusive ocular injury. In particular, this therapy is useful in the treatment of exudative ARMD and diabetic retinopathy.

The initiation of new blood vessel formation may arise quite differently in various tissues or as a result of different diseases. Many substances have been found to induce neovascularization, see, Folkman, et al., Angiogenic Factors, Science, Volume 235, pp. 442-447 (1987). However, it is believed, that once initiated, the process of neovascularization is similar in all tissues and regardless of the associated disease, Furcht, Critical Factors Controlling Angiogenesis: Cell Products, Cell Matrix, and Growth Factors, Laboratory Investigation, Volume 55, No. 5, pp. 505-509 (1986).

There are a variety of theories regarding the mechanism of action of angiostatic steroids. For example, angiostatic steroid induced inhibition of neovascularization may occur due to, dissolution of the capillary basement membrane, Ingber, et al., Supra; inhibition of vascular endothelial cell proliferation, Cariou, et al., Inhibition of Human Endothelial Cell Proliferation by Heparin and Steroids, Cell Biology International Reports, Vol. 12, No. 12, pp. 1037-1047 (December, 1988); effect on vascular endothelial cell laminin expression, Tokida, et al., Production of Two Variant Laminin Forms by Endothelial Cells and Shift of Their Relative Levels by Angiostatic Steroids, The Journal of Biological Chemistry, Vol. 264, No. 30, pp. 18123-18129 (Oct. 25, 1990); inhibition of vascular cell collagen synthesis, Maragoudakis, et al., Antiangiogenic Action of Heparin Plus Cortisone is Associated with Decreased Collagenous Protein Synthesis in the Chick Chorioullantoic Membrane System, The Journal of Pharmacology and Experimental Therapeutics, Vol. 251, No. 2, pp. 679-682 (1989); and inhibition of vascular endothelial cell plasminogen activator activity, Ashino-Fuse, et al., Medroxyprogesterone Acetate, An Anti-Cancer and Anti-Angiogenic Steroid, Inhibits the Plasminogen Activator in Bovine Endothelial Cells, Int. J. Cancer, 44, pp. 859-864 (1989).

There are many theories associated with the cause of neovascularization, and there may be different inducers depending on the disease or surgery involved, BenEzra, Neovasculogenic Ability of Prostaglandins, Growth Factors, and Synthetic Chemoattractants, American Journal of Ophthalmology, Volume 86, No.4, pp. 455-461, (October, 1978). Regardless of the cause or the associated disease or surgery, it is believed that angiostatic agents work by inhibiting one or more steps in the process of neovascularization. Therefore, the angiostatic steroids of this invention are usefuil in the treatment and prevention of neovascularization associated with a variety of diseases and surgical complications.

The angiostatic steroids of the present invention may be incorporated in various formulations for delivery to the eye. For example, topical formulations can be used and can include ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, buffers, sodium chloride, and water to form aqueous sterile ophthalmic solutions and suspensions. In order to prepare sterile ophthalmic ointment formulations, an angiostatic steroid is combined with a preservative in an appropriate vehicle, such as mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations comprising the angiostatic steroids of the present invention can be prepared by suspending an angiostatic steroid in a hydrophilic base prepared from a combination of, for example, Carbopol (a carboxy vinyl polymer available the BF Goodrich Company) according to published formulations for analogous ophthalmic preparations. Preservatives and antimicrobial agents may also be incorporated in such gel formulations. Ocular injection (intravitreal, subtenons, subconjunctival, periocular, retrobulbar) as well as intraocular slow release devices and implants may be used, particularly for delivery to the back of the eye. Systemic formulations, for example, orally ingested tablets and formulations for intraocular injection are also contemplated.

The specific type of formulation selected will depend on various factors, such as the angiostatic steroid or its salt being used, the dosage frequency, and the location of the neovascularization being treated. Topical ophthalmic aqueous solutions, suspensions, ointments, and gels are the preferred dosage forms for the treatment of neovascularization in the front of the eye (the cornea, iris, trabecular meshwork); or neovascularization of the back of the eye if the angiostatic agent can be formulated such that it can be delivered topically and the agent is able to penetrate the tissues in the front of the eye. The angiostatic steroid will normally be contained in these and other formulations in an amount from about 0.01 to about 15.0 weight/percent. Preferable concentrations range from about 0.1 to about 7.5 weight/percent. Thus, for topical administration, these formulations are delivered to the surface of the eye one to six times a day, depending on the routine discretion of the skilled clinician. Systemic administration, for example, in the form of tablets is useful for the treatment of neovascularization particularly of the back of the eye, for example, the retina. Tablets containing 10-100 mg of angiostatic agent can be taken 2-3 times per day depending on the discretion of the skilled clinician.

The compounds, no matter how delivered, can be administered prior to, during, and/or after PDT. It is preferred to administer the compounds both before and after surgury to slow or prevent the reoccurrence of neovascularization.

The following examples illustrate formulations of the present invention, but are in no way limiting.

EXAMPLE 1

Topical Ocular Formulation
Ingredient Amount (wt. %)
Anecortave Acetate 1.0
Tyloxapol 0.01 to 0.05
HPMC 0.5
Benzalkonium Chloride 0.01
Sodium Chloride 0.8
Edetate Disodium 0.01
NaOH/HCl q.s. pH 7.4
Purified Water q.s. l00 mL

The formulation is prepared by first placing a portion of the purified water into a beaker and heating to 90° C. The hydroxypropylmethylcellulose (HPMC) is then added to the heated water and mixed by means of vigorous vortex stirring until all of the HPMC is dispersed. The resulting mixture is then allowed to cool while undergoing mixing in order to hydrate the HPMC. The resulting solution is then sterilized by means of autoclaving in a vessel having a liquid inlet and a hydrophobic, sterile air vent filter.

The sodium chloride and the edetate disodium are then added to a second portion of the purified water and dissolved. The benzalkonium chloride is then added to the solution, and the pH of the solution is adjusted to 7.4 with 0.1M NaOH/HCl. The solution is then sterilized by means of filtration.

The 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate is sterilized by either dry heat or ethylene oxide. If ethylene oxide sterilization is selected, aeration for at least 72 hours at 50° C. is necessary. The sterilized 4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate is weighed aseptically and placed into a pressurized ballmill container. The tyloxapol, in sterilized aqueous solution form, is then added to the balimill container. Sterilized glass balls are then added to the container and the contents of the container are milled aseptically at 225 rpm for 16 hours, or until all particles are in the range of approximately 5 microns.

Under aseptic conditions, the micronized drug suspension formed by means of the preceding step is then poured into the HPMC solution with mixing. The ballmill container and balls contained therein are then rinsed with a portion of the solution containing the sodium chloride, the edetate disodium and benzalkonium chloride. The rinse is then added aseptically to the HPMC solution. The final volume of the solution is then adjusted with purified water and, if necessary, the pH of the solution is adjusted to pH 7.4 with NaOH/HCl. The formulation will be given topically, in a therapeutically effective amount. In this instance, the phrase “therapeutically effective amount” means an amount which is sufficient to substantially prevent or reverse any ocular neovascularization. The dosage regimen used will depend on the nature of the neovascularization, as well as various other factors such as the patient's age, sex, weight, and medical history.

EXAMPLE 2

Topical Ocular Formulation
Ingredient Amount (wt. %)
Anecortave Acetate 1.0
Mannitol 2.40
Sodium Chloride 0.40
Carbopol 974P 0.50
Polysorbate 80 0.05
Edetate Disodium 0.01
Benzalkonium Chloride 0.01 + 5% XS
Sodium Hydroxide adjust pH to 7.2
Purified Water qs to 100%

EXAMPLE 3

Tablet:

5-100 mg anecortave acetate with inactive ingredients such as starch, lactose and magnesium stearate can be formulated according to procedures known to those skilled in the art of tablet formulation.

EXAMPLE 4

Formulation for Sterile Intraocular Injection
each mL contains:
4,9(11)-Pregnadien-17α,21-diol-3,20-dione 10-100 mg
Sodium Chloride 7.l4 mg
Potassium Chloride 0.38 mg
Calcium chloride dihydrate 0.154 mg
Magnesium chloride hexahydrate 0.2 mg
Dried sodium phosphate 0.42 mg
Sodium bicarbonate 2.1 mg
Dextrose 0.92 mg
Hydrochloric acid or sodium hydroxide
to adjust pH to approximately 7.2
Water for injection

EXAMPLE 5

Sterile Injection Formulation
List of Components mg/ml
Anecortave Acetate 0.1-150 (0.0 for vehicle)
Monobasic Sodium Phosphate, Monohydrate 0.1-5
Diabasic Sodium Phosphate, Anhydrous 0.1-5
Tyloxapol 0.0-10
Sodium Chloride 0.1-10
Hydrochloric Acid and/or Sodium Hydroxide Adjust pH 7.0-7.8
Water for Injection q.s.

EXAMPLE 6

Sterile Injection formulation
List of Compounds mg/ml
Anecortave Acetate 60
Monobasic Sodium Phosphate, Monohydrate 0.45
Dibasic Sodium Phosphate, Anhydrous 2.0
Tyloxapol 4.0
Sodium Chloride 7.0
Hydrochloric Acid and/or Sodium Hydroxide Adjust pH 7.4 ± 0.2
Water for Injection q.s

EXAMPLE 7

Inhibition of Angiogenesis in the Rabbit Corneal Neovascularization Model:

The corneal pocket system of BenEzra (Am. J. Ophthalmol 86:455-461, 1978) was used to induce corneal neovascularization in the rabbit. A small Elvax pellet containing 0.5 μg of lipopolysaccharidc (LPS) was inserted into the middle of the corneal stroma and positioned 2.5 mm from the limbus. An additional Elvax pellet with or without 50 μg of angiostatic steroid was placed next to the LPS implant. The eyes were examined daily and the area of neovascularization calculated. Results after 8 days of LPS implantation are shown in FIG. 1. THF—tetrahydrocortisol; A=4,9(11)-Pregnadien-17α,21-diol-3,20-dione-21-acetate; B=4,9(11)-Pregnadien-17α,21-diol-3,20-dione. As can be seen, A & B totally inhibited corneal neovascularization, whereas THF partially inhibited the neovascular response.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4771042Jan 24, 1986Sep 13, 1988The Upjohn CompanyInhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
US4975537May 15, 1989Dec 4, 1990The Upjohn CompanyΔ9(11) -angiostatic steroids
US5371078Sep 8, 1992Dec 6, 1994Alcon Laboratories, Inc.Angiostatic steroids and methods and compositions for controlling ocular hypertension
WO1991019731A1May 23, 1991Dec 26, 1991Upjohn CoSteroids which inhibit angiogenesis
WO1995024930A1Mar 14, 1994Sep 21, 1995Massachusetts Eye & Ear InfirmUse of green porphyrins in ocular diagnosis and therapy
Non-Patent Citations
Reference
1Anderson, et al., Photochemistry and Photobiology, "Phthalocyanine Photodynamic Therapy: Disparate Effects of Pharmacolognic Inhibitors on Cutaneous Photosensitivity and on Tumor Regression," vol. 65(5):895-901; 1997.
2Ashino-Fuse, et al., Medroxyprogesterone Acetate, An Anti-Cancer and Anti-Angiogenic Steroid, Inhibits the Plasminogen Activator in Bovine Endothelial Cells, Int. J. Cancer, vol. 44:859-864, 1989.
3Asrani & Zeimer, Feasibility of Laser Targeted Photo-Occlusion of Ocular Vessels, Br J Ophthalmol., vol. 79(8):776-770, Aug., 1995.
4Asrani et al, Feasibility of Laser Targeted Photoocclusion of the Choriocapillary Layer in Rats, Investigative Ophthalmol. & Vis. Sci., vol. 38(13):2702-2710, Dec., 1997.
5BenEzra, Neovasculogenic Ability of Prostaglandins, Growth Factors, and Synthetic Chemoattractants, American Journal of Ophthalmology, vol. 86(4):455-461, Oct., 1978.
6Cariou, et al., Inhibition of Human Endothelial Cell Proliferation by Heparin and Steroids, Cell Biology International Reports, vol. 12(12):1037-1047, Dec., 1988.
7Clark, Abbot F., Exp. Opin. Invest. Drugs, "Cardiovascular & Renal AL-3789: a novel ophthalmic angiostatic steroid," vol. 6(12):1867-1877, 1997.
8Cowled, et al., Cancer Letters, "Potentiation of Photodynamic Therapy with Haematoprphyrin Derivatives by Glucocorticoids," vol. 29:107-114, 1985.
9Crum, et al., A New Class of Steroids Inhibits Angiogenesis In the Presence of Heparin or Heparin Fragment, Science, vol. 230:1375-1378, Dec. 20, 1985.
10DeFaller, J.M., Database Dissertation Abstracts University Microfilms International, "Mechanisms of Action and Clinical Efficacy of AL-3789, an Angiostatic Steroid (Neovascularization, Pterigium, Tumor Growth)," vol. 58/06B:2974.
11Folkman, et al., Angiogenic Factors, Science, vol. 235, pp. 442-447, 1987.
12Furcht, Critical Factors Controlling Angiogenesis: Cell Products, Cell Matrix, and Growth Factors, Laboratory Investigation, vol. 55(5):505-509, 1986.
13Gragoudas et al, Results and Preliminary Dosimetry of Photodynamic Therapy for Choroidal Neovascularization . . . , Investigative Ophthalmology & Visual Science, vol. 38(4):S17, Mar. 15, 1997.
14Husain et al, Photodynamic Therapy and Digital Angiography of Experimental Iris Neovascularization Using Liposomal Benzoporphyrin Derivative; Ophthalmology, vol. 104(8):1242-1250, Aug., 1997.
15Ingber, et al., A Possible Mechanism for Inhibition of Angiogenesis by Angiostatic Steroids: Induction of Capillary Basement Membrane Dissolution, Endocrinology, vol. 119(4):1768-1775, 1986.
16Li, et al., Angiostatic Steroids Potentiated by Sulphated Cyclodextrin Inhibit Corneal Neovascularization, Investigative Ophthalmology and Visual Science, vol. 32(11):2898-2905, Oct., 1991.
17Lin et al, The Photodynamic Occlusion of Choroidal Vessels Using Benzoporphyrin Derivative, Curr Eye Res, vol. 13(7):513-522, Jul., 1994.
18Maragoudakis, et al., Antiangiogenic Action of Heparin Plus Cortisone is Associated with Decreased Collagenous Protein Synthesis in the Chick Chorioallantoic Membrane System, The Journal of Pharmacology and Experimental Therapeutics, vol. 251(2):679-682, 1989.
19Miller, et al., Arch Ophthalmol. "Photodynamic Therapy of Experimental Choroidal Neovascularization Using Lipoprotein-Delivered Benzoporphyrin," vol. 113:810-818, 1995.
20Nirankari, Verinder S., Tr. AM. Ophtal. Soc., "Laser Photocoagulation for Corneal Stromal Vascularization," vol. LXXXX, pp. 595-669, 1992.
21Sickenberg et al, Preliminary Results of Photodynamic Therapy for Choroidal Neovascularization in . . . , Investigative Ophthalmology & Visual Science, vol. 38(4):S92, Mar. 15, 1997.
22Thomas et al, Purlytin(TM) (SnET2)-Photodynamic Therapy Produces Closure or Subfoveal Choroidal . . . , Investigative Ophthalmology & Visual Science, vol. 39(4):S242, Mar. 15, 1998.
23Thomas et al, Purlytin™ (SnET2)-Photodynamic Therapy Produces Closure or Subfoveal Choroidal . . . , Investigative Ophthalmology & Visual Science, vol. 39(4):S242, Mar. 15, 1998.
24Tokida, et al., Production of Two Variant Laminin Forms by Endothelial Cells and Shift of Their Relative Levels by Angiostatic Steroids, The Journal of Biological Chemistry, vol. 265(30):18123-18129, Oct. 25, 1990.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6602274Mar 18, 1999Aug 5, 2003Light Sciences CorporationTargeted transcutaneous cancer therapy
US6723750Mar 15, 2002Apr 20, 2004Allergan, Inc.Photodynamic therapy for pre-melanomas
US6806364Jul 29, 2002Oct 19, 2004Ast Products, Inc.Ophthalmic compositions
US6828356Jul 29, 2002Dec 7, 2004Ast Products, Inc.Immersing a polymeric demulcent in water, agitating to dissolve, materials handling; use for dry eye syndrome, eye disorders
US7261529Sep 7, 2005Aug 28, 2007Southwest Research InstituteApparatus for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US7288106Oct 2, 2003Oct 30, 2007Light Sciences Oncology, Inc.System and method for excitation of photoreactive compounds in eye tissue
US7572913 *Feb 24, 2005Aug 11, 2009Bioaxone Therapeutique Inc.Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine
US7758778Sep 7, 2005Jul 20, 2010Southwest Research InstituteMethods for preparing biodegradable microparticle formulations containing pharmaceutically active agents
US8158669 *Oct 18, 2007Apr 17, 2012Qlt, Inc.Improved photodynamic treatment against subfoveal choroidal neovascularization; administering midostaurin, vatalanib dihydrochloride or octreotide with a photosensitive porphyrin or purpurin; angiogenesis inhibition
US8227457Oct 19, 2011Jul 24, 2012Dmi Acquisition Corp.Method for treatment of diseases
US8586568Mar 25, 2011Nov 19, 2013Ampio Pharmaceuticals, Inc.Methods and products for treatment of diseases
US8679089Oct 17, 2007Mar 25, 2014Michael S. BerlinGlaucoma surgery methods and systems
US8722651Jul 12, 2006May 13, 2014Ampio Pharmaceuticals, Inc.Methods and products for treatment of diseases
US20120203162 *Apr 16, 2012Aug 9, 2012Qlt Inc.Method for treating neovascularization
WO2004011460A2Jul 23, 2003Feb 5, 2004Kinetek Pharmaceuticals IncPyrazolylbenzothiazole derivatives and their use as therapeutic agents
WO2004011544A1 *Jul 29, 2003Feb 5, 2004Ast Products IncOphtalmic compositions
WO2004073607A2 *Feb 4, 2004Sep 2, 2004Alcon IncUse of steroids to treat ocular disorders
WO2004112796A1 *Jun 18, 2004Dec 29, 2004Alcon IncTreatment of amd with combination of ingredients
Classifications
U.S. Classification514/177, 514/185, 514/178, 514/912
International ClassificationA61P27/02, A61F9/007, A61K31/569, A61K31/57, A61K31/56, C07J3/00, C07J9/00, A61K31/565, C07J5/00, C07J11/00, C07J51/00, C07J41/00
Cooperative ClassificationY10S514/912, C07J51/00, A61K31/573, C07J5/0053, A61K31/56, A61K31/57, C07J41/0005, C07J9/00, A61K31/565, C07J3/00, C07J41/0027, C07J11/00
European ClassificationA61K31/56, C07J51/00, A61K31/565, C07J5/00C1, C07J41/00B, C07J11/00, A61K31/57, C07J41/00B4, C07J9/00, C07J3/00, A61K31/573
Legal Events
DateCodeEventDescription
Nov 24, 2009FPExpired due to failure to pay maintenance fee
Effective date: 20091002
Oct 2, 2009LAPSLapse for failure to pay maintenance fees
Apr 13, 2009REMIMaintenance fee reminder mailed
Jul 21, 2008ASAssignment
Owner name: ALCON RESEARCH, LTD., TEXAS
Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:021266/0729
Effective date: 20080101
Owner name: ALCON RESEARCH, LTD.,TEXAS
Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;US-ASSIGNMENT DATABASE UPDATED:20100203;REEL/FRAME:21266/729
Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;US-ASSIGNMENT DATABASE UPDATED:20100309;REEL/FRAME:21266/729
Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;US-ASSIGNMENT DATABASE UPDATED:20100330;REEL/FRAME:21266/729
Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;US-ASSIGNMENT DATABASE UPDATED:20100406;REEL/FRAME:21266/729
Free format text: MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:21266/729
Apr 4, 2005FPAYFee payment
Year of fee payment: 4
Mar 26, 2001ASAssignment
Owner name: ALCON MANUFACTURING, LTD., TEXAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON LABORATORIES, INC.;REEL/FRAME:011667/0559
Effective date: 20010322
Dec 2, 1999ASAssignment
Owner name: ALCON LABORATORIES, INC., TEXAS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CLARK, ABBOT F.;REEL/FRAME:010661/0026
Effective date: 19991202
Owner name: ALCON LABORATORIES, INC. R&D LEGAL DEPARTMENT Q-14